Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Proteasome inhibitors (PIs) are established therapeutics for hematologic malignancies such as multiple myeloma (MM).
• The ubiquitin-proteasome system regulates critical cellular processes, making it a key therapeutic target.
• Bortezomib, a widely used PI, has improved MM outcomes but has limitations including peripheral neuropathy.

Purpose of the Study:

• To summarize proteasome inhibitors currently in clinical and preclinical development.
• To highlight the advantages of newer PIs over existing therapies like bortezomib.

Main Methods:

• Review of clinical and preclinical data on proteasome inhibitors.
• Comparative analysis of bortezomib with emerging PI agents.

Main Results:

• Bortezomib is effective but associated with dose-limiting peripheral neuropathy.
• Emerging PIs demonstrate potential for enhanced specificity, safety, and tolerability.
• Several novel PIs are advancing through clinical trials.

Conclusions:

• Newer proteasome inhibitors represent a promising advancement in cancer therapy.
• These agents may overcome the limitations of current treatments, offering improved patient outcomes.
• Continued investigation of novel PIs is warranted for hematologic malignancies.